New England Journal of Medicine· 2017Q1· Clinical trial
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
- 1,476citations
- Q1SCImago
- 2017year
Short summary
In postmenopausal women with osteoporosis, 12 months of romosozumab followed by alendronate significantly reduced the risk of vertebral fractures by 48% and clinical fractures by 27% compared to alendronate alone over 24 months.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Orthopedics and Sports Medicine
Orthopedics and Sports MedicineMedicine